People with systemic lupus erythematosus (SLE) who stick closely to their antimalarial medication plan early in treatment may be less likely to need hospital care later on, according to a new population-based study.
Researchers found that people with SLE who took at least 90 percent of their prescribed antimalarial doses had 21 percent fewer hospital days over the following year. They also had 11 percent fewer hospital admissions compared with people who took less than the prescribed dose. The study also found lower hospitalization costs among those who stayed on treatment.
The findings matter because lupus can increase the risk of serious complications, including inflammation, infections, kidney disease, and heart problems that may lead to emergency care or hospital stays. The study suggests that taking antimalarial medications consistently early after diagnosis may help reduce some of those risks.
Antimalarial drugs were originally developed to prevent and treat malaria, but they are now commonly used to help manage autoimmune diseases like lupus. Hydroxychloroquine (Plaquenil) is the most widely used antimalarial medication for SLE.
Most people in the new study were taking hydroxychloroquine, while a small number took chloroquine.
These medications help calm an overactive immune system. For people with lupus, antimalarials may reduce joint pain, rashes, fatigue, and disease flares. Previous research has also linked hydroxychloroquine to lower risks of kidney disease and cardiovascular problems.
As with all medications, hydroxychloroquine and chloroquine can cause side effects. Common side effects may include stomach cramps, nausea, loss of appetite, and bloating.
Although these medications are generally considered safe for long-term use, in rare cases, they can affect the retina (the light-sensitive tissue at the back of the eye) or cause other serious side effects.
Researchers analyzed health data from more than 26,000 people in British Columbia, Canada, who were newly diagnosed with either lupus or rheumatoid arthritis and had started antimalarial treatment between 1997 and 2022.
The study compared people who took at least 90 percent of their prescribed doses with those who took less.
Compared with participants who did not take the medication as prescribed, people who stayed on antimalarial treatment had:
Researchers said the findings remained strong even after accounting for factors such as age, other health conditions, and use of additional medications.
Because this was an observational study, the findings show an association, not proof of cause and effect. The researchers also noted that prescription refill records cannot confirm whether medication was actually taken, and the data didn’t include some factors that can affect lupus outcomes, such as disease activity or reasons people stopped or missed treatment.
On MyLupusTeam, people share their experiences with lupus, get advice, and find support from others who understand.
Have you taken an antimalarial medication for SLE? Did it help? Let others know in the comments below.
Get updates directly to your inbox.
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.